Molecular Partners AG (NASDAQ:MOLN - Free Report) - Leerink Partnrs issued their Q2 2025 earnings estimates for shares of Molecular Partners in a report issued on Thursday, May 15th. Leerink Partnrs analyst J. Chang expects that the company will post earnings per share of ($0.53) for the quarter. The consensus estimate for Molecular Partners' current full-year earnings is ($1.93) per share. Leerink Partnrs also issued estimates for Molecular Partners' Q3 2025 earnings at ($0.53) EPS and Q4 2025 earnings at ($0.53) EPS.
Molecular Partners (NASDAQ:MOLN - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.11). Molecular Partners had a negative net margin of 1,043.01% and a negative return on equity of 39.31%.
Separately, Lifesci Capital began coverage on Molecular Partners in a report on Tuesday, March 11th. They set an "outperform" rating and a $12.00 target price on the stock.
Check Out Our Latest Stock Analysis on MOLN
Molecular Partners Stock Performance
Shares of MOLN stock traded up $0.16 during mid-day trading on Monday, hitting $4.05. 10,089 shares of the stock traded hands, compared to its average volume of 21,031. The company's 50-day simple moving average is $3.94 and its 200-day simple moving average is $4.78. The firm has a market cap of $163.68 million, a price-to-earnings ratio of -1.89 and a beta of 1.15. Molecular Partners has a twelve month low of $3.36 and a twelve month high of $12.70.
Hedge Funds Weigh In On Molecular Partners
A hedge fund recently raised its stake in Molecular Partners stock. BVF Inc. IL boosted its holdings in Molecular Partners AG (NASDAQ:MOLN - Free Report) by 205.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,353,968 shares of the company's stock after buying an additional 910,747 shares during the quarter. BVF Inc. IL owned 3.35% of Molecular Partners worth $6,458,000 as of its most recent SEC filing. Institutional investors own 26.55% of the company's stock.
About Molecular Partners
(
Get Free Report)
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
Read More
Before you consider Molecular Partners, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Molecular Partners wasn't on the list.
While Molecular Partners currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
